A 'designer drug' that touched off a mysterious epidemic of parkinsonism has provided insights into a basic pathologic process of the disease - destruction of dopaminergic neurons. These insights have also helped correlate clinical approaches with biomedical events, opening the way for development of more effective pharmacologic agents for a still relentlessly progressive disorder.
|Original language||English (US)|
|Number of pages||32|
|Publication status||Published - 1987|
ASJC Scopus subject areas